Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$94.2M, compared with -$73.92M a year earlier. Trailing-twelve-month EBITDA was -$359.29M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 13 analysts of -$313.25M (-3.3%) for the fiscal year ending Dec 2026, a step up from the -66.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$94.2M-12.6% QoQ
- Last fiscal yearDec 2025
- -$303.13M-66.1% YoY
- LTMSep 2026
- -$359.29M-31.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.4% | +100.6% | +128.0 pp |
| 1 year | -66.1% | -3.3% | +62.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (303.13M) USD
- Year-over-year change
- -66.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (303.13M) | -66.1% |
| FY2024 | 2024-12-31 | (182.46M) | -48.5% |
| FY2023 | 2023-12-31 | (122.85M) | +42.5% |
| FY2022 | 2022-12-31 | (213.57M) | -28.0% |
| FY2021 | 2021-12-31 | (166.88M) | — |
EBITDA vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 EBITDA of -$359.29M is the 8th highest of the 10 companies compared; the peer median is -$118.15M.
- Its year-over-year change of -31.7% is the 9th highest of 10, against a peer median of +5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $949.9M | +39.8% | +41.2% | 25.7% | |
| LTM Sep 2026 | $140.29M | +5.0% | — | 11.7% | |
| LTM Jun 2026 | -$15.87M | -109.6% | -34.8% | 1.9% | |
| LTM Dec 2025 | -$38.87M | +24.6% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M | -28.2% | — | 590.7% |
| LTM Jun 2026 | -$176.13M | +22.9% | — | 22.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| LTM Sep 2026 | -$359.29M | -31.7% | — | — | |
| LTM Sep 2026 | -$434.65M | -30.9% | — | — | |
| LTM Jun 2026 | -$498.21M | -6.5% | — | 13823.7% | |
| Peer median (excluding PRAX) | -$118.15M | +5.0% | +3.2% | 24.2% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| Weighted Avg Shares | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Weighted Avg Shares (Diluted) | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.